All Categories

Home > BLOG > Ozagrel Sodium for Injection

Ozagrel Sodium for Injection

April 06,2023


The main ingredient of this product is sodium ozagrel.

Chemical name: Trans-3- [4 (1H imidazol-1-ylmethyl) phenyl] -2-sodium acrylate. Chemical structural formula: Molecular formula: C 13H 11N 2NaO 2 Molecular weight: 250.23character

This product is a white or almost white loose block or powder.

As a generic drug supplier in China, Feiyue Pharmaceutical can provide finished drugs such as Ozagrel Sodium for InjectionInjection

Packaging: 40mg ; 60mg ; 80mg

FEIYUE recruits agents worldwide, we can provide complete registration documents.


Used to treat acute thrombotic cerebral infarction and motor disorders associated with cerebral infarction.

Usage and dosage

For adults, 80mg should be administered twice a day, dissolved in 500ml of physiological saline or 5% glucose solution, intravenously for 2 weeks as a course of treatment.

Adverse reactions

Blood: Due to the tendency to bleed, it is important to observe carefully and stop administering medication immediately if any abnormalities occur. Liver and kidney: Occasional elevation of GOT, GPT, and BUN. Digestive system: occasional nausea, vomiting, diarrhea, loss of appetite, and bloating. Allergic reactions: Occasional cases of urticaria, rash, etc. Stop administering medication when they occur. Circulation system: Occasional supraventricular arrhythmias. Reduce or terminate medication when blood pressure drops. Others: occasional headaches, fever, injection site pain, shock, and thrombocytopenia. Severe adverse reactions can include hemorrhagic cerebral infarction, epidural hematoma, intracranial hemorrhage, gastrointestinal bleeding, subcutaneous bleeding, etc.


The following patients are prohibited: 1. Those who are allergic to this product; 2. Patients with cerebral hemorrhage or cerebral infarction accompanied by bleeding; 3. Individuals with severe heart, lung, liver, and kidney dysfunction, such as severe arrhythmia or myocardial infarction; 4. Individuals with hematological disorders or a tendency to bleed; 5. Severe hypertension, with systolic blood pressure exceeding 200mmHg.

matters needing attention

This product should not be mixed with calcium containing infusion (Grimm's solution, etc.) to avoid white turbidity.

Drug interactions

This product, when used in combination with antiplatelet aggregators, thrombolytic agents, and other anticoagulants, can enhance the tendency to bleed. It should be used with caution and reduced in dosage if necessary.

Drug overdose

Once excessive medication occurs, targeted treatment is necessary to maintain supportive treatment, with a focus on monitoring coagulation function and timely and appropriate treatment.

Pharmacology and Toxicology

Pharmacological effects: This product is an efficient and selective inhibitor of thromboxane synthase. It improves the imbalance between the two by inhibiting the production of thromboxane A2 (TXA2) and promoting the production of prostacyclin (PGI2). It has anti platelet aggregation and vasodilation effects. It can inhibit cerebral vasospasm, increase cerebral blood flow, improve microcirculation disorders and energy metabolism abnormalities in the brain, so as to improve the cerebral ischemia symptoms of patients after subarachnoid hemorrhage surgery and motor disorders of patients with cerebral thrombosis (acute phase). Toxicity study: Repeated administration toxicity: Intravenous injection of this product into rats and dogs. In the high-dose group of rats, a slight increase in urine electrolyte excretion was observed, and no other abnormal reactions were observed. The maximum tolerance dose for rats is 125mg/kg, and the maximum tolerance dose for dogs is 10-12.5 mg/kg. Reproductive toxicity: After intravenous injection of this product in rats and rabbits, the weight gain of animals was inhibited, and embryo death, fetal development inhibition and newborn animal death occurred in large doses. In the teratogenic sensitivity test of rats, there was a slight increase in the number of fetuses with visceral and skeletal abnormalities in the high-dose group.


Shading and sealed storage (10-30 ℃).